Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia

Leukemia

Volumn 28, Issue 2, 2014, Pages 417-419

  Bellanger, D ^a,b   Jacquemin, V ^a,b   Chopin, M ^c   Pierron, G ^a,b   Bernard, O A ^d,e   Ghysdael, J ^a,f,g   Stern, M H ^a,b  

^a INSTITUT CURIE   (France)

^b INSTITUT CURIE   (France)

^c INSERM   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f CNRS   (France)

^g INSERM U1005   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMANS; JANUS KINASE 1; JANUS KINASE 3; LEUKEMIA, PROLYMPHOCYTIC, T-CELL; MUTATION;

EID: 84893803763     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.271     Document Type: Letter

References (13)

1. Dungarwalla M, Matutes E, Dearden CE. Prolymphocytic leukaemia of B-and T-cell subtype: a state-of-the-art paper. Eur J Haematol 2008; 80: 469-476.
2. Soulier J, Pierron G, Vecchione D, Garand R, Brizard F, Sigaux F et al. A complex pattern of recurrent chromosomal losses and gains in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer 2001; 31: 248-254.
3. Vainchenker W, Constantinescu SN. JAK/STAT signaling in hematological malignancies. Oncogene 2013; 32: 2601-2613.
4. Carron C, Cormier F, Janin A, Lacronique V, Giovannini M, Daniel MT et al. TELJAK2 transgenic mice develop T-cell leukemia. Blood 2000; 95: 3891-3899.
5. Gritti C, Dastot H, Soulier J, Janin A, Daniel MT, Madani A et al. Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood 1998; 92: 368-373.
6. Yamashita Y, Yuan J, Suetake I, Suzuki H, Ishikawa Y, Choi YL et al. Array-based genomic resequencing of human leukemia. Oncogene 2010; 29: 3723-3731.
7. Elliott NE, Cleveland SM, Grann V, Janik J, Waldmann TA, Dave UP. FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma. Blood 2011; 118: 3911-3921.
8. Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L et al. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med 2008; 205: 751-758.
9. Kameda T, Shide K, Shimoda HK, Hidaka T, Kubuki Y, Katayose K et al. Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. Int J Hematol 2010; 92: 320-325.
10. Bouchekioua A, Scourzic L, de Wever O, Zhang Y, Cervera P, Aline-Fardinet A et al. JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. Leukemia 2014; 28: 338-348.
11. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 2012; 481: 157-163.
12. Koskela HLM, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmä ki H, Andersson EI et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med 2012; 366: 1905-1913.
13. Couronné L, Scourzic L, Pilati C, Della Valle V, Duffourd Y, Solary E et al. STAT3 mutations identified in human hematological neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica 2013; 98: 1748-1752.